Bristol-Myers Squibb’s (NYSE:BMY) $7 billion acquisition of Amylin Phramaceuticals (NASDAQGS:AMLN) is one of the largest diabetes deals for the year to date. Given Bristol-Myers Squibb’s and AstraZeneca’s (NYSE:AZN) five-year-old diabetes drug development alliance, the latest deal stands to position them in stronger competition with Sanofi, Novo Nordisk and Merck. As part of the deal, AstraZeneca […]
Bristol-Myers Squibb (NYSE:BMY) and Sanofi (NYSE:SNY) bid goodbye to their exclusive patent for blockbuster drug Plavix with the U.S. Food and Drug Administration’s approval of generic versions of the blood-thinning drug to nine pharmaceutical companies today, signaling the drug’s fall down the patent cliff. Plavix reached peak sales of more than $7 billion last year, […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The U.S. Food and Drug Administration is reviewing epidural injections of steroids to treat neck and back pain following a warning by Bristol-Myers Squibb (NYSE:BMY) seven months ago that administering its Kenalog steroid around the spine could cause serious complications, according to a report by Bloomberg. Bristol-Myers in New York revised its label for Kenalog […]
Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca’s (NYSE:AZN) jointly developed treatment for type 2 diabetes has been turned down by U.S. regulators until lingering questions over the diabetes drug’s benefits and risks are addressed. The U.S. Food and Drug Administration has requested additional clinical data on dapagliflozin to better assess the benefit-risk profile for the drug, including […]